首页> 美国卫生研究院文献>EFSA Journal >Opinion on the re‐evaluation of ascorbyl palmitate (E 304i) as a food additive in foods for infants below 16 weeks of age and the follow‐up of its re‐evaluation as a food additive for uses in foods for all population groups
【2h】

Opinion on the re‐evaluation of ascorbyl palmitate (E 304i) as a food additive in foods for infants below 16 weeks of age and the follow‐up of its re‐evaluation as a food additive for uses in foods for all population groups

机译:关于再评估抗坏血酸棕榈酸酯(E 304i)作为婴儿食品添加剂的食品添加剂以及作为所有人口群体食品中的食物添加剂的再次评估的随访

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ascorbyl palmitate (E 304(i)) was re‐evaluated in 2015 by the former Panel on Food Additives and Nutrient sources added to Food ( ). As a follow‐up to this assessment, the Panel on Food Additives and Flavourings ( ) was requested to assess the safety of ascorbyl palmitate (E 304(i)) for its uses as food additive in food for infants below 16 weeks of age belonging to food categories 13.1.1 (Infant formulae) and 13.1.5.1 (Dietary foods for infants for special medical purposes and special formulae for infants) and as carry over in line with Annex , Part 5 Section B to Regulation ( ) No 1333/2008. In addition, the Panel was requested to address the issues already identified during the re‐evaluation of the food additive when used in food for the general population. The process involved the publication of a call for data to allow the interested business operators to provide the requested information to complete the risk assessment. On the basis of the data submitted by interested business operators and the considerations from the Panel, a revision of the existing specifications for ascorbyl palmitate (E 304 (i)) has been recommended. Based on in vitro data, the Panel assumed that ascorbyl palmitate fully hydrolyses pre‐systemically to ascorbic acid and palmitate. The Panel concluded that the intake of both metabolites, at the s for ascorbyl palmitate as a food additive in infant formula belonging to 13.1.1 or in food for special medical purposes belonging to 13.1.5.1, does not raise health concerns.
机译:前者在2015年通过前者在食品添加剂和营养来源中重新评估抗坏血酸棕榈酸酯(e 304(i))。作为本评估的后续行动,要求食品添加剂和调味料()小组评估抗坏血酸棕榈酸酯的安全性(e 304(i))作为婴儿在归属于16周龄的婴儿的食物中用作食物添加剂的用途食品类别13.1.1(婴儿公式)和13.1.5.1(婴儿的饮食食品,用于特殊医疗用途和婴儿的特殊配方),并根据附件携带,第5部分B部​​分()第1333/2008部分。此外,要求小组在为一般人群中用于食品时重新评估食品添加剂期间已识别的问题。该过程涉及发布呼叫,以允许感兴趣的业务运营商提供所要求的信息以完成风险评估。根据感兴趣的业务运营商提交的数据以及从小组的考虑,建议修改现有的抗坏血酸棕榈酸棕榈酸(E 304(I))。基于体外数据,小组认为抗坏血基棕榈酸酯全身全身水解,抗坏血酸和棕榈酸酯。该小组得出结论:在属于13.1.1或属于13.1.5.1的特殊医疗目的的婴幼儿配方中,在抗坏血酸中作为食品添加剂的抗坏血腺棕榈酸盐的摄入量。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号